EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi

Key Takeaways INCY won EC approval for Minjuvi with lenalidomide and rituximab to treat follicular lymphoma.The decision was backed by inMIND trial data showing improved progression-free survival.INCY continues diversifying beyond Jakafi as Minjuvi gains new labels across the world. Incyte (INCY) announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab).The drug, in combination with Revlimid (lenalidomide) and rituximab, is now indicated for the treatment of adult p ...